HomeComparePCST vs ABBV

PCST vs ABBV: Dividend Comparison 2026

PCST yields 1941.75% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PCST wins by $11.99M in total portfolio value
10 years
PCST
PCST
● Live price
1941.75%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.09M
Annual income
$115,443.35
Full PCST calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PCST vs ABBV

📍 PCST pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCSTABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCST + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCST pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCST
Annual income on $10K today (after 15% tax)
$165,048.54/yr
After 10yr DRIP, annual income (after tax)
$98,126.85/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PCST beats the other by $77,070.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCST + ABBV for your $10,000?

PCST: 50%ABBV: 50%
100% ABBV50/50100% PCST
Portfolio after 10yr
$6.10M
Annual income
$70,107.55/yr
Blended yield
1.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PCST
No analyst data
Altman Z
-40.1
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCST buys
0
ABBV buys
0
No recent congressional trades found for PCST or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCSTABBV
Forward yield1941.75%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$12.09M$102.3K
Annual income after 10y$115,443.35$24,771.77
Total dividends collected$8.50M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PCST vs ABBV ($10,000, DRIP)

YearPCST PortfolioPCST Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$107,787$97,087.38$11,550$430.00+$96.2KPCST
2$604,342$489,009.07$13,472$627.96+$590.9KPCST
3$1,927,848$1,281,202.25$15,906$926.08+$1.91MPCST
4$3,972,625$1,909,827.67$19,071$1,382.55+$3.95MPCST
5$6,089,723$1,839,014.80$23,302$2,095.81+$6.07MPCST
6$7,833,324$1,317,320.55$29,150$3,237.93+$7.80MPCST
7$9,173,477$791,819.60$37,536$5,121.41+$9.14MPCST
8$10,248,932$433,311.61$50,079$8,338.38+$10.20MPCST
9$11,192,577$226,220.10$69,753$14,065.80+$11.12MPCST
10$12,091,501$115,443.35$102,337$24,771.77+$11.99MPCST

PCST vs ABBV: Complete Analysis 2026

PCSTStock

Nova Corps, LLC was incorporated in 2018 and is based in Bloomington, Minnesota.

Full PCST Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PCST vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCST vs SCHDPCST vs JEPIPCST vs OPCST vs KOPCST vs MAINPCST vs JNJPCST vs MRKPCST vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.